- In January 2025, Eli Lilly & Company launched Orforglipron, an oral GLP-1 receptor agonist aimed at weight loss. The medication is expected to be an accessible alternative to injectable treatments like Wegovy, showing promising results in clinical trials. The launch marks a significant advancement in obesity management.
- In December 2024, Novo Nordisk introduced Wegovy semaglutide injection for weight management, which has gained significant traction in the market for obesity treatment. Despite challenges with FDA enforcement on compounded versions, Wegovy continues to be a leader in weight loss medications.
- In October 2024, Haag-Streit USA unveiled its METIS Ophthalmic Microscope, offering exceptional optical performance for delicate medical procedures. This launch, while focused on ophthalmic surgery, reflects the company's ongoing investment in precision healthcare technologies, which indirectly supports patient care in weight management by enhancing overall health monitoring capabilities.
- In November 2024, Nourish, a nutrition-focused startup, achieved a $1 billion valuation with its virtual nutritional care services, which are now covered by insurance for weight loss management. This initiative expands access to professional dietary support for individuals using weight loss drugs like Wegovy.
